1. Home
  2. TNET vs NAMS Comparison

TNET vs NAMS Comparison

Compare TNET & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TriNet Group Inc.

TNET

TriNet Group Inc.

HOLD

Current Price

$62.41

Market Cap

3.0B

ML Signal

HOLD

Logo NewAmsterdam Pharma Company N.V.

NAMS

NewAmsterdam Pharma Company N.V.

HOLD

Current Price

$21.61

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TNET
NAMS
Founded
1988
2019
Country
United States
Netherlands
Employees
2700
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
2.8B
IPO Year
2000
2022

Fundamental Metrics

Financial Performance
Metric
TNET
NAMS
Price
$62.41
$21.61
Analyst Decision
Hold
Strong Buy
Analyst Count
7
16
Target Price
★ $66.20
$50.65
AVG Volume (30 Days)
251.2K
★ 1.9M
Earning Date
10-28-2026
11-04-2026
Dividend Yield
★ 1.81%
N/A
EPS Growth
N/A
★ 32.81
EPS
★ 3.05
N/A
Revenue
★ $5,010,000,000.00
$22,503,000.00
Revenue This Year
N/A
$29.51
Revenue Next Year
$3.80
$383.46
P/E Ratio
$20.97
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$33.67
$21.02
52 Week High
$73.08
$42.21

Technical Indicators

Market Signals
Indicator
TNET
NAMS
Relative Strength Index (RSI) 38.53 36.31
Support Level $59.61 $21.02
Resistance Level $64.37 $37.26
Average True Range (ATR) 1.87 1.28
MACD -0.44 0.19
Stochastic Oscillator 8.54 16.02

Price Performance

Historical Comparison
TNET
NAMS

About TNET TriNet Group Inc.

Trinet Group Inc provides human resources solutions for small and medium-sized businesses through technology-enabled services. Its offerings include human capital expertise, employee benefits such as health insurance and retirement plans, payroll and payroll tax administration, risk mitigation, and compliance consulting. The company provides its services through professional employer organization (PEO) services delivered via a co-employment model, as well as administrative services organization (ASO) offerings. The majority of the company's revenue is derived from the insurance-related billings and administrative fees collected from PEO clients.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Share on Social Networks: